868735-81-3

Basic information

• Product Name: 1-(Benzyloxy)-2,3-Difluoro-4-Nitrobenzene
• Synonyms: 1-(Benzyloxy)-2,3-Difluoro-4-Nitrobenzene
• CAS NO: 868735-81-3
• Molecular Formula: C₁₃H₉F₂NO₃
• Molecular Weight: 265.2122664
• Mol File: 868735-81-3.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1-(Benzyloxy)-2,3-Difluoro-4-Nitrobenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(Benzyloxy)-2,3-Difluoro-4-Nitrobenzene(868735-81-3)
• EPA Substance Registry System: 1-(Benzyloxy)-2,3-Difluoro-4-Nitrobenzene(868735-81-3)

Safety Data

• Hazardous Substances Data: 868735-81-3(Hazardous Substances Data)

Usage

Structure

Benzene derivative with two fluorine atoms, a nitro group, and a benzyloxy group attached to the carbon atom

Functional groups

Fluorine atoms, nitro group, and benzyloxy group

Application

Used in organic synthesis and pharmaceutical research

Pharmacological properties

Potential biological activities due to the presence of a nitro group and difluoromethyl group

Synthesis

Can be used as a starting material for the synthesis of other complex organic compounds

Importance

An important compound in the field of chemistry and pharmaceuticals due to its potential uses and properties

Upstream product

• 771-69-7 2,3,4-trifluoronitrobenzene 
• 100-51-6 benzyl alcohol 
• 2105-61-5 1,2,4-trifluoro-5-nitrobenzene 
• 123173-60-4 2,3-difluoro-4-nitrophenol 

Downstream Products

• 163733-99-1 4-amino-2,3-difluoro-phenol 
• 1020173-31-2 2,3-difluoro-4-[2-(1-methyl-1H-pyrazol-4-yl)-pyridin-4-yloxy]phenylamine 
• 115551-33-2 2-hydroxy 3,4-difluoro aniline 
• 1437323-99-3 4-(6,7-dimethoxyquinolin-4-yloxy)-2,3-difluorophenylamine 
• 868735-84-6 4-(4-amino-2,3-difluorophenoxy)picolinamide 
• 1552280-92-8 4-(4-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamido)-2,3-difluorophenoxy)picolinamide 

Relevant articles and documents

Discovery of a Pyrimidinedione Derivative as a Potent and Orally Bioavailable Axl Inhibitor

The receptor tyrosine kinase Axl plays important roles in promoting cancer progression, metastasis, and drug resistance and has been identified as a promising target for anticancer therapeutics. We used molecular modeling-assisted structural optimization starting with the low micromolar potency compound 9 to discover compound 13c, a highly potent and orally bioavailable Axl inhibitor. Selectivity profiling showed that 13c could inhibit the well-known oncogenic kinase Met with equal potency to its inhibition of Axl superfamily kinases. Compound 13c significantly inhibited cellular Axl and Met signaling, suppressed Axl- and Met-driven cell proliferation, and restrained Gas6/Axl-mediated cancer cell migration or invasion. Furthermore, 13c exhibited significant antitumor efficacy in Axl-driven and Met-driven tumor xenograft models, causing tumor stasis or regression at well-tolerated doses. All these favorable data make 13c a promising therapeutic candidate for cancer treatment.

SUBSTITUTED PYRAZOLONE COMPOUNDS AND METHODS OF USE

The present invention provides novel substituted pyrazolone compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.

SUBSTITUTED QUINOLINE COMPOUNDS AND METHODS OF USE

The present invention provides novel substituted quinoline compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.